Predictive value of lipoprotein(a) in coronary artery calcification among asymptomatic cardiovascular disease subjects: A systematic review and meta-analysis

• Published in: Nutrition, metabolism, and cardiovascular diseases Vol. 33; no. 11; pp. 2055 - 2066
• Main Authors: Vazirian, Fatemeh, Sadeghi, Masoumeh, Kelesidis, Theodoros, Budoff, Matthew J., Zandi, Zahra, Samadi, Sara, Mohammadpour, Amir Hooshang
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.11.2023
• Subjects: Adult; Aged; Asymptomatic Diseases; atherosclerosis; biomarkers; Biomarkers - blood; blood; CAC; calcification; cardiovascular disease; confidence interval; Coronary Artery Disease - blood; Coronary Artery Disease - diagnosis; Coronary Artery Disease - diagnostic imaging; Coronary Artery Disease - epidemiology; coronary vessels; Female; Humans; Incidence; lipoprotein(a); Lipoprotein(a) - blood; lipoproteins; Male; meta-analysis; metabolism; Middle Aged; nutrition; odds ratio; Predictive Value of Tests; Prognosis; risk; Risk Assessment; Risk Factors; systematic review; Up-Regulation; Vascular Calcification - blood; Vascular Calcification - diagnosis; Vascular Calcification - diagnostic imaging; Vascular Calcification - epidemiology; atherosclerosis; meta-analysis; cardiovascular disease; CAC; lipoprotein(a)
• ISSN: 0939-4753; 1590-3729; 1590-3729
• DOI: 10.1016/j.numecd.2023.07.015

Studies have indicated inconsistent results regarding the association between plasma levels of Lipoprotein(a) [Lp(a)] and coronary artery calcification (CAC). We performed a systematic review and meta-analysis to investigate the association between elevated levels of Lp(a) and risk of CAC in populations free of cardiovascular disease (CVD) symptoms. PubMed, Web of Science, Embase, and Scopus were searched up to July 2022 and the methodological quality was assessed using Newcastle–Ottawa Scale (NOS) scale. Random-effects meta-analysis was used to estimate pooled odds ratio (OR) and 95% confidence interval. Out of 298 studies, data from 8 cross-sectional (n = 18,668) and 4 cohort (n = 15,355) studies were used in meta-analysis. Cohort studies demonstrated a positive significant association between Lp(a) and CAC, so that individuals with Lp(a)≥30–50 exposed to about 60% risk of CAC incidence compared to those with lower Lp(a) concentrations in asymptomatic CVD subjects (OR, 1.58; 95% CI, 1.38–1.80; l2, 0.0%; P, 0.483); Subgroup analysis showed that a cut-off level for Lp(a) measurement could not statistically affect the association, but race significantly affected the relationship between Lp(a) and CAC (OR,1.60; 95% CI, 1.41–1.81). Analyses also revealed that both men and women with higher Lp(a) concentrations are at the same risk for increased CAC. Blood Lp(a) level was significantly associated with CAC incidence in asymptomatic populations with CVD, indicating that measuring Lp(a) may be a useful biomarker for diagnosing subclinical atherosclerosis in individuals at higher risk of CAC score. CRD42022350297. [Display omitted] •Elevated Lp(a) level is an independent marker for identifying CVD asymptomatic individuals who are at risk of CAC incidence.•In populations free of CVD symptoms, individuals with Lp(a)≥30–50 exposed to about 60% risk of CAC incidence.•Race could potentially affect the relationship between Lp(a) and CAC.•Both men and women with higher Lp(a) concentrations are at the same risk for increased CAC.